BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18790773)

  • 1. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes.
    Stahnke B; Thepen T; Stöcker M; Rosinke R; Jost E; Fischer R; Tur MK; Barth S
    Mol Cancer Ther; 2008 Sep; 7(9):2924-32. PubMed ID: 18790773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells.
    Schiffer S; Letzian S; Jost E; Mladenov R; Hristodorov D; Huhn M; Fischer R; Barth S; Thepen T
    Cancer Lett; 2013 Dec; 341(2):178-85. PubMed ID: 23973499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model.
    Tur MK; Huhn M; Jost E; Thepen T; Brümmendorf TH; Barth S
    Int J Cancer; 2011 Sep; 129(5):1277-82. PubMed ID: 21077160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.
    Tur MK; Huhn M; Thepen T; Stöcker M; Krohn R; Vogel S; Jost E; Osieka R; van de Winkel JG; Fischer R; Finnern R; Barth S
    Cancer Res; 2003 Dec; 63(23):8414-9. PubMed ID: 14679004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxicity of anti-CD64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice.
    Zhong RK; van de Winkel JG; Thepen T; Schultz LD; Ball ED
    J Hematother Stem Cell Res; 2001 Feb; 10(1):95-105. PubMed ID: 11276363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins.
    Schiffer S; Rosinke R; Jost E; Hehmann-Titt G; Huhn M; Melmer G; Barth S; Thepen T
    Int J Cancer; 2014 Sep; 135(6):1497-508. PubMed ID: 24523193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Hydra HALT-1 as a toxin moiety for recombinant immunotoxin.
    Jiemy WF; Hiew LF; Sha HX; In LLA; Hwang JS
    BMC Biotechnol; 2020 Jun; 20(1):31. PubMed ID: 32552895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.
    Mladenov R; Hristodorov D; Cremer C; Gresch G; Grieger E; Schenke L; Klose D; Amoury M; Woitok M; Jost E; Brümmendorf TH; Fendel R; Fischer R; Stein C; Thepen T; Barth S
    Oncotarget; 2016 Oct; 7(41):67166-67174. PubMed ID: 27564103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.
    Hristodorov D; Mladenov R; Brehm H; Fischer R; Barth S; Thepen T
    MAbs; 2014; 6(5):1283-9. PubMed ID: 25517313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells.
    Hetzel C; Bachran C; Fischer R; Fuchs H; Barth S; Stöcker M
    J Immunother; 2008 May; 31(4):370-6. PubMed ID: 18391759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor.
    Niesen J; Hehmann-Titt G; Woitok M; Fendel R; Barth S; Fischer R; Stein C
    Cancer Lett; 2016 May; 374(2):229-40. PubMed ID: 26912070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant, ETA'-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice.
    Ribbert T; Thepen T; Tur MK; Fischer R; Huhn M; Barth S
    Br J Dermatol; 2010 Aug; 163(2):279-86. PubMed ID: 20426788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin.
    Dunn RD; Weston KM; Longhurst TJ; Lilley GG; Rivett DE; Hudson PJ; Raison RL
    Immunotechnology; 1996 Sep; 2(3):229-40. PubMed ID: 9373315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein.
    Goldstein J; Graziano RF; Sundarapandiyan K; Somasundaram C; Deo YM
    J Immunol; 1997 Jan; 158(2):872-9. PubMed ID: 8993006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The usefulness of CD64, other monocyte-associated antigens, and CD45 gating in the subclassification of acute myeloid leukemias with monocytic differentiation.
    Krasinskas AM; Wasik MA; Kamoun M; Schretzenmair R; Moore J; Salhany KE
    Am J Clin Pathol; 1998 Dec; 110(6):797-805. PubMed ID: 9844593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GM-CSF-DFF40: a novel humanized immunotoxin induces apoptosis in acute myeloid leukemia cells.
    Mathew M; Zaineb KC; Verma RS
    Apoptosis; 2013 Jul; 18(7):882-95. PubMed ID: 23529188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.
    Kioi M; Seetharam S; Puri RK
    Mol Cancer Ther; 2008 Jun; 7(6):1579-87. PubMed ID: 18566228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages.
    Hristodorov D; Mladenov R; Fischer R; Barth S; Thepen T
    Immunol Cell Biol; 2016 May; 94(5):470-8. PubMed ID: 26743033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human CD64-targeted non-viral siRNA delivery system for blood monocyte gene modulation.
    Yong SB; Kim HJ; Kim JK; Chung JY; Kim YH
    Sci Rep; 2017 Feb; 7():42171. PubMed ID: 28169353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.